ArticleDiscover oncology2025
A rare case of primary transverse colon adenocarcinoma penetrating the abdominal wall.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Colorectal cancer (CRC) is the third most prevalent malignancy globally and the second leading cause of cancer mortality as of 2020. Its clinical presentation varies by stage, progressing from asymptomatic early disease to advanced symptoms (e.g., rectal bleeding, bowel habit alterations), while unusual manifestations may signal locally advanced disease. Locally advanced CRC is rare, without metastasis representing a critical therapeutic window for curative surgery or neoadjuvant therapy. However, primary locally advanced CRC penetrating the abdominal wall from the intra-abdominal cavity remain unreported. In this report, we describe a rare case of a 78-year-old male who had primary invasive transverse colon adenocarcinoma penetrating the abdominal wall, forming an externally visible mass measuring approximately 9 × 5 cm without lymph node or distinct metastasis. After the pathologically diagnosis of colon adenocarcinoma, the patient received a radical resection surgery combined with abdominal wall reconstruction using a skin flap, followed by six months of capecitabine-based adjuvant chemotherapy. The patient showed no relapse or progression during the one year follow-up after the operation. This rare case highlights the ongoing challenges in managing locally advanced CRC and underscores the potential benefits of active curative treatment strategies for such patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.